| __timestamp | Bio-Techne Corporation | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 129764000 |
| Thursday, January 1, 2015 | 144969000 | 152008000 |
| Friday, January 1, 2016 | 162364000 | 209620000 |
| Sunday, January 1, 2017 | 188462000 | 241786000 |
| Monday, January 1, 2018 | 210850000 | 315264000 |
| Tuesday, January 1, 2019 | 240515000 | 359466000 |
| Wednesday, January 1, 2020 | 255497000 | 524272000 |
| Friday, January 1, 2021 | 298182000 | 470515000 |
| Saturday, January 1, 2022 | 349103000 | 483669000 |
| Sunday, January 1, 2023 | 366887000 | 577065000 |
| Monday, January 1, 2024 | 389335000 |
In pursuit of knowledge
In the ever-evolving biotech industry, understanding financial metrics like the cost of revenue is crucial for investors and stakeholders. This analysis focuses on two prominent players: Bio-Techne Corporation and BioMarin Pharmaceutical Inc., from 2014 to 2023. Over this period, Bio-Techne's cost of revenue surged by approximately 266%, reflecting its strategic investments and growth. Meanwhile, BioMarin's cost of revenue increased by about 345%, indicating its aggressive expansion and product development strategies.
Bio-Techne's cost of revenue consistently rose, peaking in 2024, while BioMarin experienced a significant jump in 2020, aligning with its product pipeline advancements. Notably, data for BioMarin in 2024 is unavailable, highlighting potential gaps in reporting or strategic shifts. This financial trajectory underscores the dynamic nature of the biotech sector, where innovation and market demands drive financial outcomes.
Comparing Cost of Revenue Efficiency: Johnson & Johnson vs Bio-Techne Corporation
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Bio-Techne Corporation vs Walgreens Boots Alliance, Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and Alkermes plc
Analyzing Cost of Revenue: Bio-Techne Corporation and Xenon Pharmaceuticals Inc.
Bio-Techne Corporation vs Vericel Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Galapagos NV
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored